Awakening 'dormant' cells to fight cancer

The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite a remarkable initial response that can be seen in a majority of patients, most of them will undergo relapse even after spectacular initial responses. These relapses are due to 'dormant' persistent cells, unresponsive to treatment.

from Top Health News -- ScienceDaily https://ift.tt/3u07bIj